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The Excreted/Secreted (ES) proteins play important roles during Mycobacterium
tuberculosis invasion, virulence, and survival inside the host and they are a major source
of immunogenic proteins. However, the molecular complexity of the bacillus cell wall
has made difficult the experimental isolation of the total bacterial ES proteins. Here,
we reported the genomes of two Beijing genotype M. tuberculosis clinical isolates
obtained from patients from Vietnam (isolate 46) and South Africa (isolate 48). We
developed a bioinformatics pipeline to predict their secretomes and observed that
∼12% of the genome-encoded proteins are ES, being PE, PE-PGRS, and PPE the
most abundant protein domains. Additionally, the Gene Ontology, KEGG pathways and
Enzyme Classes annotations supported the expected functions for the secretomes.
The ∼70% of an experimental secretome compiled from literature was contained in
our predicted secretomes, while only the 34–41% of the experimental secretome was
contained in the two previously reported secretomes for H37Rv. These results suggest
that our bioinformatics pipeline is better to predict a more complete set of ES proteins
in M. tuberculosis genomes. The predicted ES proteins showed a significant higher
antigenic density measured by Abundance of Antigenic Regions (AAR) value than the
non-ES proteins and also compared to random constructed secretomes. Additionally,
we predicted the secretomes for H37Rv, H37Ra, and two M. bovis BCG genomes. The
antigenic density for BGG and for isolates 46 and 48 was higher than the observed for
H37Rv and H37Ra secretomes. In addition, two sets of immunogenic proteins previously
reported in patients with tuberculosis also showed a high antigenic density. Interestingly,
mice infected with isolate 46 showed a significant lower survival rate than the ones
infected with isolate 48 and both survival rates were lower than the one previously
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reported for the H37Rv in the same murine model. Finally, after a druggability analysis
of the secretomes, we found potential drug targets such as cytochrome P450, thiol
peroxidase, the Ag85C, and Ribonucleoside Reductase in the secreted proteins that
could be used as drug targets for novel treatments against Tuberculosis.
Keywords: secretome, Mycobacterium tuberculosis, antigenic density, drug targets, AAR, clinical isolates,
bioinformatics, immunogenicity
INTRODUCTION
Worldwide, Mycobacterium tuberculosis (M. tuberculosis)
remains a highly prevalent pathogen. According to the WHO,
there were 10.4 million new cases and 1.4 million deaths in
2015 (WHO, 2016). Additionally, 3.3% of the new cases and
20% of the previously treated ones correspond to multidrug-
resistant (MDR) infections (WHO, 2016). Although the use
and development of rapid molecular diagnostic tests like
Xpert MTB/Rif R© and GeneXpert Omni R© has expanded, the
development of new drugs and vaccines is necessary. Moreover,
with the wide genetic variation within M. tuberculosis strains
and the impact that this variability has on the clinical outcome
(López et al., 2003; Pérez-Martínez et al., 2008), there is a great
need to understand the molecular mechanisms leading from
strain genotype to the clinical phenotype. The strain H37Rv is
the most studied M. tuberculosis strain, and it is an important
model for laboratory studies. Another important M. tuberculosis
family of strains is the “Beijing” genotype, a member of Lineage
2 (East-Asia), which has caused great concern because of their
enhanced virulence, their highly transmissible phenotypes, and
their increasing prevalence worldwide (López et al., 2003).
The complete set of Excreted/Secreted (ES) proteins, which
is often referred as the cell secretome, is involved in critical
biological processes, like mechanisms of adhesion, cell migration,
and invasion, cell-to-cell communication, signal transduction
and potential infective strategies in disease mechanisms (Tjalsma
et al., 2004). As a facultative intracellular pathogen, M.
tuberculosis relies on its ability to survive within the host through
the secretion of virulent proteins with the capacity to modulate a
variety of host cellular pathways (Smith, 2003; Målen et al., 2007;
Chande et al., 2015; Vargas-Romero et al., 2016). ES proteins
are an important source of immunogenic proteins due to their
ability to be recognized by the host immune system. They are
also considered T-cell antigens that promote protective immune
responses against M. tuberculosis (Daugelat et al., 1992; Målen
et al., 2007; Zheng et al., 2013). This has led to focusing most
vaccine and drug development efforts to the identification of
mycobacterial secreted proteins.
Several experimental attempts have been made to determine
the secretome of M. tuberculosis strains, using “traditional”
techniques such as 2-D gel electrophoresis or based on “omics”
approaches like liquid chromatography coupled with different
types of MS analysis (Målen et al., 2007). However, the
molecular complexity of the pathogen cell envelope, composed
by mycolic acids, peptidoglycan, acyl lipids, etc., complicate
the experimental analysis of ES proteins (Zhou et al., 2015).
To address this limitation, bioinformatics methods can be used
for the systematized prediction of ES proteins from available
sequenced genomes (Gomez et al., 2015). In this regard, two
predicted M. tuberculosis secretomes were previously reported
using bioinformatics approaches. In one study, the genome of
H37Rv was screened to predict their encoded ES proteins using
several secretion predictors, resulting in a secretome of 825
proteins (Vizcaíno et al., 2010). However, only one protein from
each predictor was selected and experimentally confirmed as
secreted (Vizcaíno et al., 2010). In a second study, the authors
reported a database composed of 276 secreted proteins for the
H37Rv genome using different bioinformatics algorithms (Roy
et al., 2013) and they found that 46 from 57 experimentally
confirmed secreted proteins were predicted in their secretome
(Roy et al., 2013). However, neither of the two studies provided
annotation analysis, biochemical pathway mapping, protein
domain content or antigenic potential of their M. tuberculosis
predicted secretomes. Also, the two reported secretomes could
still contain transmembrane proteins because the algorithms
used in their ES predictions do not analyze this type of proteins,
plus, success in their ES prediction was only evaluated against
few experimentally secreted proteins. In the present study,
we sequenced and assembled two genomes of M. tuberculosis
clinical isolates members of the Beijing genotype and the total
encoded proteins were independently analyzed to predict the ES
proteins for each genome. The predicted ES proteins were then
annotated regarding sequence similarity to other known proteins,
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways,
gene ontologies (GO) and protein domains. Additionally, the
antigenic density of the predicted secretomes was evaluated
using the AAR value (Gomez et al., 2015). The secretomes for
H37Rv, H37Ra and two BCG genomes were also predicted.
Finally, a druggability analysis was also made for the predicted
secretomes. We believe that our work could contribute to a
better comprehension of the host-pathogen interactions in theM.
tuberculosis infection.
METHODS
Bacterial Strains
We selected two Mycobacterium tuberculosis clinical isolates
members of the Beijing genotype that we referred as isolates
46 and 48 in this manuscript. Prof D. van Soolingen at the
National Institute of Public Health and the Environment (RIVM;
Bilthoven, the Netherlands) kindly provided the isolate 46
that corresponds to the RIVM number 2002:1612 collected in
Vietnam. This isolate is part of a tuberculosis isolates collection
from a wide range of geographical origins. The isolate 48
corresponds to the previously described clinical strain code
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1 reported in Tuberculosis patients attending primary health
care clinics in the Western Cape Province of South Africa
(Aguilar et al., 2010). This isolate was collected from the urban
epidemiological field site in Cape Town during the period
January 1993–December 2004 and kindly provided by Prof R.
Warren from the Stellenbosh University (van der Spuy et al.,
2009).
Sequencing and Assembly of
M. tuberculosis Clinical Isolates
The bacterial genomic DNA (gDNA) of the 46 and 48 isolates was
extracted from liquid cultures in logarithmic growth phase using
theQuick-gDNATM MiniPrep kit after performing Zihel-Neelsen
stains to assess the purity of M. tuberculosis cells. DNA libraries
were constructed using the NebNext DNA Library protocol from
Illumina (Cat. E6040S). Libraries were pair-end sequenced using
Illumina GAIIx technology in the Unidad de Secuenciación
Masiva from INMEGEN with a length of 72 bp per read and a
sequencing depth of approximately 8 million paired reads per
genome. The raw sequences were filtered using FastX-Toolkit
and de novo assembled using Velvet (Zerbino and Birney, 2008).
The resulting assemblies of each isolate are showed in Table S1.
The final selected assemblies were analyzed with RAST (Aziz
et al., 2008) to obtain the ORFs. We also extracted the ORFs
from the H37Rv genome (GenBank: AL123456.3) using RAST to
compare with the ones obtained for the clinical isolates.
Prediction of ES Proteins in
M. tuberculosis Genomes
All the coding gene sequences were analyzed independently
for each genome by the different feature-based tools indicated
in Figure 1. SignalP 4.1 (Bendtsen et al., 2004) was used to
predict classically secreted proteins (Sec-dependent), setting the
option for prokaryote organisms and the positional limit of 70
residues for truncation and the rest of the parameters were set
as default. SecretomeP 2.0 (Bendtsen et al., 2005a) was used to
predict the non-classical secreted proteins selecting the default
options for Gram-positive bacteria and all the resulting proteins
with an N-N score ≥ 0.5 were considered as positives. TatP
1.0 (Bendtsen et al., 2005b) was used to determine the proteins
secreted via the Tat pathway applying the default parameters
and the resulting proteins with a Tat motif were considered as
positives. Additionally, we used LipoP 1.0 (Juncker et al., 2003)
to predict lipoprotein motifs in the first 70 amino acids of each
sequence, for this program, all settings were set to default, and
all the resulting proteins with a “cytoplasmic” prediction were
removed. Finally, all the proteins considered as positive from
each of the predictors were merged together and the resulting
list was scanned by TMHMM 2.0 (Krogh et al., 2001). This
tool allows the identification, localization, and orientation of
transmembrane helices and all the proteins predicted with 0
transmembrane motifs were assigned directly as part of the
secretome. The rest of the proteins (with ≥1 transmembrane
motifs) were further analyzed with Phobius (Käll et al., 2007)
to identify possible α-helical conformations in the N-terminal
region of the proteins that belongs to a signal sequence and
that could be mistakenly classified as a transmembrane region.
If any of the analyzed proteins was predicted to have a signal
sequence it was added to the list of ES proteins. The secretome
of the M. tuberculosis H37Ra GenBank CP000611 and two M.
bovis BCG (BCG Danish GenBank NZ_CUWH01000001 and
BCG Pasteur GenBank AM408590) strains were also predicted
using the same bioinformatics pipeline. For comparison, the
proteins that are neither ES and transmembrane was defined as
“intracellular proteins.” Hence, the non-ES proteins consist of the
transmembrane and the intracellular proteins.
Annotation and Comparative Analysis of
ES Proteins
For identifying homolog proteins, ES proteins were analyzed
using BLASTP against the non-redundant (nr) database using
the Blast2GO (Conesa and Götz, 2008) with an E-value cut-
off set at 1.0E−3 (Table S2). Both ES and non-ES proteins were
functionally mapped to GO terms and annotated by setting
the following parameters: E-value-hi-filter: 1.0E−3; Annotation
cut-off: 55; GO weight: 5 and Hsp-Hit Coverage cut-off:0. The
ES proteins were also associated with protein families through
InterProScan (Zdobnov and Apweiler, 2001). Blast2GO was then
used to identify the over or under represented GO terms in
the ES proteins, by setting the term filter p-value to ≤ 0.05.
Additionally, the KAAS (Moriya et al., 2007) was used for
mapping ES proteins to KEEG pathways using the BBH (bi-
directional best hit) method to assign the representative genes
data set and the orthologs for prokaryotes (Table S3). We also
classified the enzymes according to the six enzymes commission
classes using Blast2GO (Figure S1).
Construction of the Experimental
Secretome
To validate the accuracy of our bioinformatics pipeline, we
compared an experimental validated secretome (Figure S2) that
we compiled from a literature search against our predicted
secretomes. To construct the experimental secretome, we made
a search at the NCBI database, and we retrieve all articles that
experimentally reported excreted or secreted proteins for M.
tuberculosis. After that, we ended up with 338 proteins that
have been experimentally reported as secreted in different studies
(Table S4). Then, we perform a BLASTP of the 338 proteins (E-
value 1.0E−3) against our predicted secretomes to assess how
many experimental ES proteins matched with the predicted
secretomes. Only the secreted proteins reported as markers
for serodiagnosis by Zhou et al. (2015), were also included
in the experimental secretome. To do this, we analyzed the
complete set of Zhou et al. (2015) with TMHMM and only the
proteins without transmembrane regions were included in our
experimental secretome.
Calculation of the Abundance of Antigenic
Regions (AAR)
The AAR is a value used to normalize the number of antigenic
regions by the sequence length (Gomez et al., 2015). This value
was calculated as the ratio between the sequence length and
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FIGURE 1 | Bioinformatics pipeline to identify and annotate the secretomes of M. tuberculosis genomes.
the number of predicted antigenic regions for each protein and
determines the number of amino acids that are needed to find
one antigenic region within a protein sequence (Gomez et al.,
2015). Hence, low AAR values mean that the protein has more
antigenic regions (more antigenic density). We used the AAR
value to evaluate the antigenic density of the different protein
data sets. To this end, the number of antigenic regions for each
protein sequences was obtained using BepiPred (Larsen et al.,
2006) with the default settings (threshold 0.35) and normalized
by sequence length (Gomez et al., 2015). The Mann-Whitney
statistical test (p < 0.001) was used to establish if there is a
significant difference between AAR values of protein data sets.
To assess if the AAR observed in the predicted secretomes is
significantly different to random constructed secretomes, we
compared the AAR of the predicted secretomes to the AAR of
1000 protein datasets with 553, 519, and 548 randomly selected
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proteins from 46, 48, and H37Rv genomes, respectively. We
then determined the AAR for each of the 1000 iterations and
determined an empirical p-value by keeping track of the number
of iterations equaled or exceeded the observed AAR for each
corresponding secretome.
Potential Drug Target Analysis
We performed a BLASTP (E-value 1.0E−3) between the proteins
of the 46, 48, and H37Rv secretomes to obtain the shared proteins
in the three secretomes (core secretome). The resulting set of
449 shared proteins was further searched for sequence similarity
against known drug targets available on the Drug Bank database
(http://www.drugbank.ca/), setting the E-value to 1.0E−3 and the
rest of the options to default. In Table S5 all the proteins that have
similarity with a known drug target, as well as the drugs that can
affect said target, are showed.
Survival and Drug Resistance Assays
The survival rate caused by the two clinical isolates was evaluated
in 6- to 8-week-old male BALB/c mice as previously described
(Hernandez-Pando et al., 1996). Briefly, two groups of 50 mice
were each inoculated intratracheally with 2.5 × 105 bacilli of
each of the two clinical isolates in 100µL Phosphate-Buffered
Saline (PBS) and survival rate was recorded since day 1–day 90
post-infection. The clinical isolates were also evaluated for drug
resistance (rifampicin, ethambutol, streptomycin and isoniazid)
with the BD BACTECHTM MGITTM 960 Mycobacteria Culture
System following the manufacturer’s recommendations.
Nucleotide Sequence Accession Numbers
This Whole Genome Shotgun project has been deposited
at DDBJ/ENA/GenBank under the accessions MSLU00000000
and MSLV00000000. The versions described in this paper are
MSLU01000000 and MSLV01000000.
RESULTS
Genome Sequencing and Assembly
We sequenced the whole genome of the 46 and 48M. tuberculosis
clinical isolates, which were originated of patients from Vietnam
and South Africa, respectively. Bacterial genomic DNA was
extracted from liquid cultures and sequenced using Illumina
GAIIx technology with a depth of approximately 8 million paired
reads per genome. After genome assembly, we obtained 151
contigs for isolate 46 and 144 contigs for isolate 48 (Table S1)
with approximately 71- and 72-fold genome coverage of a 4.3
Mb genome size, respectively. The Open Reading Frames (ORFs)
were extracted for each genome, resulting in 4336 and 4310
proteins for isolate 46 and 48, respectively. Additionally, we also
extracted the ORFs in the H37Rv genome to compare with the
proteins of the clinical isolates.
Prediction of M. tuberculosis Secretomes
Proteins can be secreted through multiple secretory mechanisms.
Thus, we utilized a combination of different bioinformatics
tools based on Neuronal Network (NN), Hidden Markov Model
(HMM), and Support Vector Machine (SVM) algorithms to
predict the mycobacterial ES proteins encoded in our assembled
genomes. To this end we utilized SignalP 4.1, SecretomeP
2.0, TatP 1.0, LipoP 1.0, followed by TMHMM 2.0 and
Phobius (Figure 1). Such algorithms have a high performance
in predicting signal peptides, protein subcellular localization,
and transmembrane proteins. In addition, several of these
algorithms have good performance to predict signal peptides in
mycobacterial proteins (Restrepo-Montoya et al., 2009; Vizcaíno
et al., 2010). SignalP and SecretomeP 2.0 were used to determine
the classical and non-classical secreted proteins, respectively.
Lipoproteins containing signal peptides were identified using
LipoP 1.0 and proteins containing a twin-arginine signal peptide
cleavage site were predicted using TatP 1.0. Then, the proteins
predicted as secreted through the four algorithms were merged,
yielding a set of 1956 different proteins for isolate 46, 1920
different proteins for isolate 48 and 1285 proteins for H37Rv.
Next, each protein dataset was analyzed for the presence of
transmembrane regions by TMHMM 2.0 algorithm. All the
proteins containing transmembrane regions were removed, and
the remaining proteins were considered the secretome for the
genome 46, 48, and H37Rv. The proteins with transmembrane
motifs that were removed from each isolate were re-analyzed with
Phobius to identify proteins with a α-helical conformation in the
amino section that could have been mistakenly classified as a
transmembrane region (Figure 1). From Phobius analysis, only
1 protein for isolate 46 was predicted to have a signal peptide and
therefore it was added to the secreted list of proteins. For isolate
48 and H37Rv no proteins were predicted to have a signal peptide
by Phobius. Finally, the predicted secretome of isolates 46, 48,
and H37Rv consisted of 553, 519, and 548 proteins, respectively,
which represent ∼12% of the total proteins encoded in their M.
tuberculosis genomes.
Annotation of M. tuberculosis Secretomes
Of the predicted secretomes, 448 proteins (81.01%) of isolate 46,
484 proteins (93.26%) of isolate 48, and 502 proteins (91.6%) of
H37Rv strain showed significant similarity (BLASTP matches)
with proteins deposited in the non-redundant (nr) database.
Furthermore, according with the BLASTP match, most of the
ES proteins for the three strains were identified as members of
the PE, PPE, and PGRS families (Table S2) which are known as
important in the bacterial virulence mechanisms (Brennan and
Delogu, 2002). ES proteins were then annotated for Biological
Process, Molecular Function, and Cellular Components with GO
terms using Blast2GO. This resulted in 316 (57.14%) proteins
for isolate 46, 283 (54.53%) proteins for isolate 48 and 309
(56.39%) proteins for H37Rv that were annotated with 304, 392,
and 115 different GO terms, respectively. We analyzed whether
any GO term showed a statistically significant over or under
representation in the secretome as compared to the expected
GO term distributions for the whole genome of each strain.
For the three strains a significant over/under representation was
only observed in the Cellular Component category. As expected,
the most over represented GO terms in the secretomes were
extracellular region, cell periphery and external encapsulating
structure (Figure 2), which are the typical cellular components
reported for secreted proteins (Gomez et al., 2015). While, GO
Frontiers in Microbiology | www.frontiersin.org 5 February 2017 | Volume 8 | Article 128
Cornejo-Granados et al. M. tuberculosis Secretomes: Antigenicity/Druggability
FIGURE 2 | Top 10 of significant over or under represented GO terms in
predicted secretomes. The figure shows for each significant GO term in
Cellular Component category the amount (percentage) of sequences
annotated with this term in secretomes and genomes. The Y-axis shows
significantly overrepresented (inside the ticked lines) or underrepresented GO
terms in secretome and the X-axis gives the percentage of sequences of each
term. The p-value in parentheses, shows the statistical assessment of
over/under representation of GO term in secretomes when compared to
genomes. Isolate 46 (A), isolate 48 (B), and reference strain H37Rv (C).
terms that are non-related to cellular components of secreted
proteins such as membrane part, protein complex or intrinsic
membrane component were under represented in the secretome
(Figure 2). We also used KAAS for mapping the ES proteins to
KEGG pathways. After that, a total of 132 (23.9%), 117 (22.5%),
and 121 (22.08%) ES proteins of isolates 46, 48 and H37Rv
secretomes were mapped to 74, 75, and 76 KEGG pathways,
respectively. The two most frequently mapped KEGG pathways
for each secretome were: ABC transporters and pyrimidine
metabolism. Additionally, we found two proteins involved in
beta-Lactam resistance pathway (Table S3). The Tuberculosis
KEGG pathway groups all human and M. tuberculosis proteins
that have been involved in host-pathogen interactions and as
expected five proteins were mapped to this pathway: lipoprotein
LpqH, lipoprotein LprG, phosphate transport system substrate-
binding protein pstS, acid phosphatase SapM, and the 6 kDa early
secretory antigenic target ESAT-6 (Table S3). The full pathway
annotations are available in Table S3.
We also classified the enzymes of the ES and non-ES
proteins according to the six Enzyme Commission (EC) Classes.
The results showed an overrepresentation of oxidoreductases,
isomerases, and hydrolases in the ES proteins of isolate 46 as
compared to the same enzyme types for the non-ES proteins
(Figure S1). For isolate 48, there is an overrepresentation of the
same kinds of proteins besides ligases (Figure S1B) while in strain
H37Rv there is an overrepresentation of hydrolases, isomerases,
oxidoreductases and ligases (Figure S1C). The annotation of
protein domains contained in the secretomes was conducted
using InterProScan and resulted in 274 protein domains for
isolate 46, 234 for isolate 48 and 253 protein domains for H37Rv.
The most represented protein domains are shown in Table 1.
For the three secretomes, the most represented protein domains
were PPE family C-terminal, and PE-PGRS family N-terminal.
Interestingly, these protein domains are involved in the M.
tuberculosis pathogenicity (Fishbein et al., 2015).
The Experimentally Reported ES Proteins
Confirm the Accuracy of our Predicted
Secretomes
To validate the accuracy of our bioinformatics pipeline to predict
experimental secretomes, we compiled a protein dataset of 338
proteins (Table S4) experimentally reported as excreted/secreted
in M. tuberculosis (see Methods) and determined how many
proteins of this experimental secretome were also reported
in our predicted secretomes. After that, we found that 227
(67.15%), 220 (65.09%), and 257 proteins (76.04%) of the
experimental secretome were also contained in our predicted
secretomes of isolates 46, 48, and H37Rv, respectively (Figure
S2). These data indicates that ∼70% of the experimental
secreted proteins were also included in our predicted secretomes,
showing that our bioinformatics method is quite accurate. To
asses, if the same number of experimental secreted proteins
could be found in a list of randomly selected proteins, we
constructed 1000 random secretomes consisting of groups
of 553, 519, and 548 randomly selected proteins from the
46, 48, and H37Rv genomes, respectively and matched each
random secretome against the experimental one. After that,
we found that the maximum percentage of shared proteins
obtained by a random secretome was of 40%, which is lower
than the percentage obtained with our predicted secretomes
(∼70%), indicating that our results are significantly different than
random.
Additionally, we also matched the experimental secretome
that we compiled from the literature search with the ones
previously reported by Roy et al. (2013) and Vizcaíno et al.
(2010). However, we found that only the 34.32 and 41.42% of the
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TABLE 1 | Top 10 most represented protein domains in isolate 46, 48 and
H37Rv secretomes.
InterPro code InterPro description Number of ES
proteins (%)
ISOLATE 46
IPR022171 PPE family C-terminal 18 (3.25)
IPR012338 Beta-lactamase/transpeptidase-like 18 (3.25)
IPR000084 PE-PGRS family N-terminal 17 (3.07)
IPR016040 NAD(P)-binding domain 15 (2.71)
IPR027417 P-loop containing nucleoside triphosphate
hydrolase
14 (2.53)
IPR029058 Alpha/Beta hydrolase fold 12 (2.17)
IPR012336 Thioredoxin-like fold 11 (1.99)
IPR029063 S-adenosyl-L-methionine-dependent
methyltransferase
11 (1.99)
IPR000253 Forkhead-associated (FHA) domain 8 (1.45)
IPR017853 Glycoside hydrolase superfamily 7 (1.27)
ISOLATE 48
IPR000084 PE-PGRS family N-terminal 29 (5.59)
IPR012338 Beta-lactamase/transpeptidase-like 20 (3.85)
IPR022171 PPE family C-terminal 20 (3.85)
IPR029058 Alpha/Beta hydrolase fold 18 (3.47)
IPR016040 NAD(P)-binding domain 15 (2.89)
IPR012336 Thioredoxin-like fold 14 (2.7)
IPR027417 P-loop containing nucleoside triphosphate
hydrolase
14 (2.7)
IPR029063 S-adenosyl-L-methionine-dependent
methyltransferase
9 (1.73)
IPR000253 Forkhead-associated (FHA) domain 8 (1.54)
IPR001763 Rhodanese-like domain 6 (1.16)
REFERENCE STRAIN H37Rv
IPR000084 PE-PGRS family, N-terminal 68 (12.41)
IPR022171 PPE family, C-terminal 22 (4.01)
IPR016040 NAD(P)-binding domain 14 (2.55)
IPR029058 Alpha/Beta hydrolase fold 9 (1.64)
IPR027417 P-loop containing nucleoside triphosphate
hydrolase
8 (1.46)
IPR012338 Beta-lactamase/transpeptidase-like 8 (1.46)
IPR012336 Thioredoxin-like fold 5 (0.91)
IPR007312 Phosphoesterase 5 (0.91)
IPR026954 PknH-like extracellular domain 4 (0.73)
IPR005490 L,D-transpeptidase catalytic domain 4 (0.73)
experimental secretome was shared with the secretome reported
by Roy et al. (2013) and Vizcaíno et al. (2010), respectively
(Figure S2). These results suggest that the bioinformatics pipeline
we used is better to predict a complete set of excreted/secreted
proteins inM. tuberculosis genomes.
The AAR Value Reveals a High Antigenic
Density in the Predicted and Experimental
Secretomes
The AAR was used to calculate the antigenic density of the
ES, intracellular, transmembrane and non-ES proteins of the
isolates 46 and 48 and the H37Rv genomes. We found that
the ES proteins have significantly more antigenic density (non-
parametric Mann-Whitney test p ≤ 0.01) than the rest of the
proteins encoded in the M. tuberculosis genomes (Figure 3 and
Table 2). Interestingly, the secretomes of both clinical isolates
had more antigenic density (AAR = ∼37.5) than the H37Rv
secretome (AAR = 40.6) (Table 2). However, no significant
difference between each secretome after performing the Mann-
Whitney test was observed. This result suggests that no strain
seems to have a more antigenic secretome than the other even
there was a tendency tomore antigenic secretomes for the clinical
isolates respect to H37Rv.
To validate the biological significance of the high antigenic
density (lower AAR values) observed in our secretomes, we also
calculated the antigenic density for the experimental secretome
obtained from the literature search (Table 2). Interestingly, the
antigenic density for the experimental secretome was similar
to the one obtained for the predicted secretomes (Table 2). It
has been reported that some parasite secretomes have more
antigenic density that non-secreted or transmembrane proteins
(Gomez et al., 2015; Wang et al., 2015). So, we also analyzed
if the high antigenic density is exclusive of the M. tuberculosis
secretomes or if any set of similar number of proteins could
obtain the same AAR value. To this end, we selected 1000 groups
of 553, 519, and 548 randomly selected proteins from the 46,
48, and H37Rv genomes, respectively, and calculated the AAR
for each group (see Methods). After that, we found that all the
predicted secretomes had more significantly antigenic density
(p < 0.005) than the randomly constructed ones. Hence, the
high antigenic density obtained for the predicted secretomes is
exclusive of that combination of secreted proteins. In addition,
to test whether the antigenic density of our predicted secretomes
was similar to other M. tuberculosis secretomes, we applied our
bioinformatics pipeline to obtain the secretome of the H37Ra,
BCG Danish, and BCG Pasteur genomes and calculated their
AAR values (Table 3). We selected the genome of H37Ra because
it is an attenuated strain closely related to the virulent H37Rv
strain. We also selected two substrains of the M. bovis Bacille
Calmette-Guérin (BCG) strain because it is the bacteria used
in the Tuberculosis vaccine. Interestingly, the antigenic density
for the BCG secretomes was very similar to the ones obtained
for our clinical isolates (Table 3). However, the AAR values of
the clinical isolates still show a lower tendency to have more
antigenic density, followed by BCG and H37Ra and H37Rv
strains (Table 3).
Taking the advantage of the fact that there is a lot of
information about immunogenic proteins in Tuberculosis, we
investigated if these immunogenic proteins have a high antigenic
density. To this end, we selected two sets of proteins causing
seropositive reactions in serum samples of Tuberculosis patients
and determined their AAR values. The first set contains 57
secreted proteins resulted from a screening with 10 Tb patient
and 3 healthy serum samples used as negative controls (Zhou
et al., 2015). The second set contains 12 proteins characterized as
serum biomarkers that can differentiate between both TB patients
with active disease or recovered individuals; this second set was
obtained from 189 patients (Deng et al., 2014). Interestingly, the
AAR values were 38.5 for the former and 37.8 for the later protein
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FIGURE 3 | Comparison between AAR values for Excreted/Secreted
(ES), non Excreted/Secreted (non-ES) intracellular (Incell) and
transmembrane (TM) proteins. The number of antigenic regions was
calculated using the BepiPred method. The X-axis shows the protein group
analyzed and the Y-axis shows the AAR obtained for each protein in that
dataset. Low AAR values means that a protein has more antigenic density. The
AAR comparisons between the proteins of isolate 46 (A); isolate 48 (B) and
H37Rv (C) are illustrated. A Mann-Whitney test was performed to compare the
AAR within each group with a confidence level of 99% (p ≤ 0.01),
(****p < 0.001).
TABLE 2 | Abundance of Antigenic Regions (AAR) for M. tuberculosis
predicted and experimental secretomes.
ES Proteins Non-ES proteins
M. tuberculosis
strain
Number of
proteins
in the dataset
AAR
average
Number of
proteins
in the dataset
AAR
average
Beijing isolate 46 553 37.52 3702 44.54
Beijing isolate 48 519 37.55 3743 44.56
H37Rv reference
strain
548 40.63 3788 44.74
Experimental
secretome
338 38.99 - -
TABLE 3 | Abundance of Antigenic Regions (AAR) for M. tuberculosis
strains from different lineages.
ES Proteins
M. tuberculosis strain Number of proteins
in the dataset
AAR average
Beijing isolate 46 553 37.52
Beijing isolate 48 519 37.55
H37Rv reference strain 548 40.63
H37Ra 554 40.52
BCG Danish 526 38.99
BCG Pasteur 564 38.89
dataset, suggesting that both sets of immunogenic proteins are
composed of proteins with a high antigenic density.
Predicted Secretomes Suggest Novel Drug
Targets
After a BLASTP (E-value 1.0E−3) comparison between the 46, 48,
and H37Rv secretomes we found that 449 proteins were shared
between the three secretomes. This set of proteins was named
the “M. tuberculosis core secretome” and we compared their
sequence similarity against known drug targets available on the
DrugBank database to determine if some ES proteins could be
used as potential drug targets in the host-pathogen interactions
(see Methods). Of the 449 ES proteins, only 26 showed homology
with 91 known drug targets (Table S5). Notably, of all possible
drug targets, only a few have a known inhibitor activity.
Survival and Drug Resistance Assays
We tested the survival rate of the 46 and 48 clinical isolates in
a murine model (see Methods). Mice infected with isolate 46
showed the lowest survival rate, reaching 0% at day 48, whilemice
infected with isolate 48 survived until day 82 (Figure 4). After
performing a log-rank (Mantel-Cox) test a significant difference
was observed between the two survival rates with a p value
≤0.0001. Additionally, the two isolates also showed sensibility to
rifampicin and ethambutol and resistance to streptomycin and
isoniazid (see Methods).
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FIGURE 4 | Survival rate of Beijing clinical isolates. The two
M. tuberculosis Beijing clinical isolates were used to infect BALB/c mice and
record the survival rate. The X-axis shows the days post-infection and the
Y-axis shows the percent of survival. A Log-rank (Mantel-cox) test was
performed to compare the survival percentages within each group.
DISCUSSION
To the best of our knowledge, this study contains the most
comprehensive in silico and experimental collection of M.
tuberculosis secretomes and it is the first one that takes into
account the secretome analysis of clinical isolates. Our results
showed that our bioinformatics pipeline is quite accurate to
predict a complete set of the secreted/excreted proteins in
M. tuberculosis genomes. In this regard, our data indicates
that ∼70% of the experimental secretome was also predicted
as secreted using our bioinformatics approach, while only
the 34.32 and 41.42 % of the experimental secretome was
found in the secretomes reported by Roy et al. (2013)
and Vizcaíno et al. (2010), respectively. Furthermore, the
maximum coincidence of the experimental secretome against
1000 randomly constructed secretomes was of 45.3%, indicating
that our predicted secretomes are also significantly different to
the random.
The predicted ES proteins for the three M. tuberculosis
genomes represented around∼12% of the total genome proteins.
Interestingly, this value is twice the percentage reported for the
secretomes of parasite organisms like tapeworms (Gomez et al.,
2015; Wang et al., 2015). We suggest that this difference between
the percentages of secreted proteins among parasites could be
associated with the fact that parasites such as T. solium are
extracellular pathogens while M. tuberculosis is an intracellular
parasite that requires different invasion mechanisms with their
host. The annotation of the secretomes showed an enrichment
of the antigenic protein families such as the PPE and PE-
PGRS (Table 1 and Table S2). It has been observed that these
proteins may play a role in evasion of host immune responses,
possibly via antigenic variation (Chaitra et al., 2008; Sampson,
2011; Akhter et al., 2012). As expected, several immunodominant
antigens widely known for M. tuberculosis such as ESAT-6,
Ag85C, CFP21, and CFP-10 (Silva et al., 2003; Wang et al.,
2005) and several proteins of the Tuberculosis KEGG pathway
(Table S3) were also present in our predicted secretomes. The
overrepresentation of hydrolases and oxidoreductases in our
predicted secretomes (Figure S1) is in agreement with the
enrichment of this enzyme types reported in experimental M.
tuberculosis secretomes (Målen et al., 2007). It is recognized
that T-cells primarily mediate the immune response against an
intracellular pathogen like M. tuberculosis. However, secreted
and transmembrane proteins have also been identified to be
targeted by B-cells in other intracellular bacteria like Listeria and
Chlamydia (Grenningloh et al., 1997; Bannantine et al., 2000). In
this regard, we chose BepiPred algorithm to analyze the antigenic
density of the ES proteins, which predicts linear B-cell epitopes
using Hidden Markov Models (Larsen et al., 2006). Interestingly,
the predicted secretomes showed a significant higher antigenic
density than the non-ES proteins (Figure 3). Additionally, a
high antigenic density was also observed for the experimental
secretome (Table 2). These results are in agreement with the high
antigenic density reported for secretomes of 14 helminth species,
including the human parasite T. solium (Gomez et al., 2015).
The antigenic density observed for the secretomes of the
avirulent H37Ra and the virulent H37Rv strains was very similar,
suggesting that the antigenic density is not associated with the
virulence in these two strains. In fact, the avirulent phenotype
of H37Ra is mainly associated to the loss of a secretion system
(Zheng et al., 2008). The antigenic density between the two M.
bovis BCG strains was very similar (AAR=∼39) but it was higher
than the antigenic density of the H37Rv (AAR= 40.6). In this
case, the low virulence observed for the BCG strains is mainly
attributed to the loss of RD1 locus, affecting the protein secretion
pathway and the loss of cytolytic activity mediated by secreted
ESAT-6, leading to reduced tissue invasiveness (Millington et al.,
2011). However, the tendency to more antigenic density in the
secretomes of BCG as compared to the H37Rv suggests why BCG
strain has been the only one used as a vaccine so far. The higher
antigenic density of all analyzed secretomes was the observed
for the isolates 46 and 48 (AAR= ∼37.5). This high antigenic
density could be associated to the strong and sustained antigen
stimulation for the granuloma formation and promoting the cell
necrosis observed for Beijing strains (Flynn, 2004). Recently, it
was suggested that M. tuberculosis uses mechanisms other than
antigenic variation to evade T cells, indicating that antigenic
variation is not a major mechanism of immune evasion in this
pathogen (Coscolla et al., 2015). Interestingly, our data suggest
that increasing the antigenic density of their secretomes could be
one of the mechanisms associated with hypervirulent phenotypes
of Beijing strains. In this regard, our survival assays performed
in the tuberculosis murine model showed that isolates 46 and 48
have significantly lower survival rate than the one reported for the
H37Rv (Hernandez-Pando et al., 1996). However, the antigenic
density between two clinical isolates was very similar, AAR =
37.52 for isolate 46 and AAR = 37.55 for isolate 48, suggesting
that the antigenic density is not the only mechanism responsible
of the hypervirulent phenotype of these two Beijing strains.
The clinical isolates 46 and 48 showed a resistance to
streptomycin and isoniazid, which are two of the first-line
antibiotics used as treatment against Tuberculosis. It is necessary
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to explore not only the drugs acting at the intracellular level
in M. tuberculosis, but also the drugs acting on proteins
associated to the host-pathogen interactions. In this regard,
it has been reported that several M. tuberculosis ES proteins
interact with host cellular proteins to establish a successful
infection modulating the host immune responses (Sreejit et al.,
2014). The identification of this type of ES proteins may
help us to design drugs against the host-pathogen interactions.
For example, some virulence blockers are used to inhibit the
secreted toxins of pathogens such as Bacillus anthracis, and
Clostridium tetani (Moayeri et al., 2006; Clatworthy et al., 2007).
Similarly, some studies have examined the potential of inhibiting
extracellular molecules that participate in quorum sensing and
help microorganisms such Pseudomonas aeruginosa in the
biofilms formation (Duncan et al., 2012). Thus, the inhibition
of ES proteins that are important for successful M. tuberculosis
infection via disruption of host-pathogen interactions could
help us to establish new opportunities for treatments against
Tuberculosis.
In the core secretome we found homologous to known drug
targets (Table S5), opening the possibility that known drugs
could be used against ES proteins of M. tuberculosis. The
list of drug targets includes the Ribonucleoside Reductase a
homolog target used in cancer chemotherapy and several drugs
including gallium nitrate and imexon were found to target this
enzyme (Table S5). The gallium nitrate inhibits the activity
of the Ribonucleoside Reductase and this drug has proven a
high efficacy to treat Tuberculosis in murine models (Olakanmi
et al., 2013). While imexon increases oxidative stress in target
cells but also inhibits the Ribonucleoside Reductase (Roman
et al., 2011). Nonetheless, there are not studies using this drug
to Tuberculosis treatment. In basis on the above mentioned
results, we suggest that several drugs (Table S5) usually used for
cancer therapy, such as imexon and motexafin gadolinium could
be explored as potential novel treatments against Tuberculosis
through themodulation of the Ribonucleoside Reductase enzyme
activity. However, it is important to mention that the human
Ribonucleotide Reductase is also target of these cancer therapy
drugs and secondary effects of a treatment using these drugs
should be also evaluated. We also found several drugs that are
in experimental phase (Table S5). Hence, their pharmacological
action on the target protein is unknown. Some of them are:
S-Oxy Cysteine, vitamin A, Pegvisomant, and Sofalcone which
are target of the thiol peroxidase, short-chain dehydrogenase,
cytochrome P450 (CYP139) and short chain dehydrogenase,
respectively. Sofalcone suppress the production of NO and TNF
in macrophages in vitro (Tanaka et al., 2009). Interestingly, these
two citokines are responsible for the chronic inflammation and
pneumonia in the late stages of M. tuberculosis infection. The
CYP139 is immediately downstream of three polyketide synthase
genes (pks17, 9, and 11) and upstream of genes encoding an ATP-
binding ABC transporter, which is likely involved in the carriage
(probably export) of macrolide molecules across the membrane
(McLean and Munro, 2008). Hence, the CYP139 could be
involved in the modification of these polyketide molecules prior
to the transport process and it could be associated with the
host-pathogen interactions.
The Ag85C is an essential protein for the cell wall synthesis in
M. tuberculosis (Gobec et al., 2004). Recently, it was reported that
Ebselen inhibits the growth of drug-resistant strains inhibiting
the Ag85 complex (Favrot et al., 2013), demonstrating that it is an
important target for the development of novel anti-Tuberculosis
agents (Gobec et al., 2004). Thus, the two drugs reported in our
analysis that also target the Ag85C (Table S5) could also be used
to explore their effect on M. tuberculosis. Additionally, we also
found a Class A beta-lactamase, which is a potential target for the
Avibactam drug. Interestingly, it has been recently reported that
clinical isolates of M. tuberculosis are susceptible to β-lactam/β–
lactamase inhibitor combinations (Cohen et al., 2016). However,
to date only the β-Lactamase inhibition by Avibactam has been
proved in M. abscessus (Dubée et al., 2015). The Avibactam
has no useful intrinsic antibacterial activity per se, it shows
good results when it is combined with a β-lactam antibacterial
as ceftazidime such as in the Avycaz which was recently used
for treatment of intra-abdominal and urinary tract infections,
including acute pyelonephritis, and it also has been used against
carbapenemase-producing Enterobacteriaceae (Lucasti et al.,
2013). These studies suggest that Avibactam in combination with
other β-lactam antibiotics, such as Avycaz could be used against
Tuberculosis.
The combination of SignalP, SecretomeP, TatP, and LipoP
to predict the secreted proteins gives us the advantage to
obtain proteins that were secreted through different secretion
mechanisms and the use of TMHMM allows the elimination
of secreted proteins containing transmembrane regions. We
suggest that the combination of bioinformatics tools we designed
allowed us a good match between experimental and predicted
secretomes (Figure S2). For example, the secretome reported
by Vizcaíno et al. (2010) also used the same 4 predictors that
we used; however, they do not eliminate the transmembrane
proteins in their secretome. While the secretome reported by
Roy et al. (2013), only utilized the secreted proteins by SignalP
followed by TATFIND1.4, PRED-LIPO, and the application of
TMHMM analysis but only in a selected subgroup of proteins.
Our bioinformatics pipeline could be useful to predict secretomes
in other pathogen bacteria genomes. Undoubtedly, it would
be ideal to support the secretome analysis with RNAseq data
allowing us the identification of ES proteins that are differentially
expressed duringM. tuberculosis infection. For example, only the
41% of the Taenia solium secretome was reported as expressed
(Gomez et al., 2015) while the 91% of the E. multilocularis
secretome was differentially expressed between the parasite life-
cycle stages (Wang et al., 2015). Our study contributes to increase
the knowledge of the molecular mechanisms of host-pathogen
interactions and we demonstrated how the ES proteins could
be novel therapeutic targets against Tuberculosis using known
drugs. Finally, a web server to calculate the AAR from protein
datasets is under construction.
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